文献速递免疫规划传染病防控与疫情报告

鼻内减毒活疫苗或肌注mRNA加强接种可增强混合免疫并阻断SARS-CoV-2 XBB.1.5传播

Boosting hybrid immunity with intranasal live-attenuated or intramuscular mRNA vaccination prevents SARS-CoV-2 XBB.1.5 transmission.
PubMed 文献 · Vaccine · 2026-10-28

研究在叙利亚仓鼠模型中模拟既往混合免疫(肌注二价mRNA疫苗后感染SARS-CoV-2),再分别给予异源鼻内OTS-LAV或肌注mRNA XBB.1.5加强接种。两种加强策略均显著提升系统和黏膜部位的XBB.1.5结合抗体与中和抗体,但未改变SARS-CoV-2特异性T细胞频率。所有混合免疫动物均免于XBB.1.5攻击后发病,仅加强接种后完全阻断病毒传播,且与鼻样本中无感染性病毒相关。

要点

  • 鼻内OTS-LAV或肌注mRNA XBB.1.5加强均能提升系统和黏膜抗体应答。
  • 加强接种未改变SARS-CoV-2特异性T细胞频率。
  • 仅加强接种后完全阻断XBB.1.5传播,与鼻样本无感染性病毒相关。

核心结论

  • 鼻内OTS-LAV加强接种可有效增强既往混合免疫并限制SARS-CoV-2传播。
  • 变异株适配的加强接种能高效限制传播,对应对新发呼吸道感染有重要价值。

研究设计与样本

  • 使用叙利亚仓鼠模型,先肌注二价mRNA疫苗后感染SARS-CoV-2模拟既往混合免疫。
  • 随后异源给予鼻内OTS-LAV或肌注mRNA XBB.1.5加强接种,并进行XBB.1.5攻击感染。

主要发现

  • 两种加强策略均显著增加系统和黏膜部位的XBB.1.5结合抗体与中和抗体。
  • 加强接种后SARS-CoV-2特异性T细胞频率未发生变化。
  • 所有混合免疫动物均免于XBB.1.5攻击后发病。
  • 仅加强接种后完全阻断病毒传播,且与鼻样本中无感染性病毒相关。

临床怎么用

  • 支持将鼻内OTS-LAV作为异源加强策略用于增强既往混合免疫。
  • 变异株适配加强接种可用于限制SARS-CoV-2传播。

局限性

  • 证据来自叙利亚仓鼠模型,尚未在人体中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rapid antigenic evolution of SARS-CoV-2 and waning immunity have reduced antibody-mediated neutralization, enabling breakthrough infections and sustained transmission despite widespread immunity. This highlights the need for variant-adapted booster vaccines. However, pre-existing immunity may influence the magnitude and specificity of immune responses induced by variant-adapted booster vaccination. Using the Syrian hamster model, we previously described a safe and efficient mucosal vaccination approach using live attenuated viruses (LAV) based on a "One-to-Stop (OTS)" codon modification strategy. Whether OTS vaccines are suitable as effective booster vaccines in the presence of pre-existing mucosal immunity remained unaddressed. Here, we modeled pre-existing hybrid immunity in Syrian hamsters using intramuscular bivalent mRNA vaccination followed by SARS-CoV-2 infection and subsequently administered heterologous intranasal OTS-LAV or intramuscular mRNA XBB.1.5 booster vaccination. Both booster strategies significantly increased XBB.1.5-binding- and neutralizing antibodies systemically and at mucosal sites. In contrast, booster vaccination left SARS-CoV-2 specific T cell frequencies unchanged. While all hybrid-immune animals were protected from disease following XBB.1.5 challenge infection, virus transmission was completely blocked only after booster vaccination and was associated with the absence of infectious virus in nasal samples. Collectively, using OTS-LAV we provide a proof of concept that intranasal LAV vaccination can effectively boost pre-existing hybrid immunity and restrict viral transmission. These findings support the use of OTS-LAV as a heterologous booster strategy against SARS-CoV-2 and demonstrate that variant-adapted booster vaccination can efficiently limit transmission, a strategy highly desired for tackling emerging respiratory infections.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kochmann J, Halwe NJ, Barut GT, et al. Boosting hybrid immunity with intranasal live-attenuated or intramuscular mRNA vaccination prevents SARS-CoV-2 XBB.1.5 transmission. Vaccine. 2026. PMID: 42950580. doi:10.1016/j.vaccine.2026.129298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。